Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Balk

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
Cancer Research|November 22, 2022
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingJesse C Patterson, Andreas Varkaris, Peter J P Croucher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Nature Communications|May 27, 2026
RNAs anchoring replication complex control initiation and firing of DNA replicationSimone Ummarino, Larysa Poluben, Alexander K Ebralidze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2018
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate CancerElahe A Mostaghel, Ailin Zhang, Susana Hernandez, et al.
The Journal of Clinical Investigation|June 9, 2026
Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancerRhea Sahu, Miriam Enos, Swastika Sharma, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.
Nature Genetics|September 2, 2020
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancerShuai Gao, Sujun Chen, Dong Han, et al.
The Journal of Clinical Investigation|December 1, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
Urology|September 17, 2002
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancerPeter R Carroll, Philip W Kantoff, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Cancer Research|November 22, 2022
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor SignalingJesse C Patterson, Andreas Varkaris, Peter J P Croucher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Nature Communications|May 27, 2026
RNAs anchoring replication complex control initiation and firing of DNA replicationSimone Ummarino, Larysa Poluben, Alexander K Ebralidze, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2018
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate CancerElahe A Mostaghel, Ailin Zhang, Susana Hernandez, et al.
The Journal of Clinical Investigation|June 9, 2026
Epigenetic and oncogenic inhibitors converge to drive a metabolic catastrophe in castration-resistant prostate cancerRhea Sahu, Miriam Enos, Swastika Sharma, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.
Nature Genetics|September 2, 2020
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancerShuai Gao, Sujun Chen, Dong Han, et al.
The Journal of Clinical Investigation|December 1, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
Urology|September 17, 2002
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancerPeter R Carroll, Philip W Kantoff, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Pageof 19